The Effect of Hormonal Therapy on the Behavioral Outcomes in 47,XXY (Klinefelter Syndrome) between 7 and 12 Years of Age.
47,XXY
SCA
behavior
early hormonal treatment
hormonal replacement therapy
sex chromosomal aneuploidy
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
06 07 2023
06 07 2023
Historique:
received:
22
05
2023
revised:
23
06
2023
accepted:
04
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
47,XXY, also known as Klinefelter syndrome, is the most commonly occurring sex chromosomal aneuploidy (SCA). Hormonal replacement therapy (HRT) has been associated with improved neurodevelopmental capabilities in boys with 47,XXY, although studies investigating HRT's possible positive effect on behavioral outcomes are scarce. This study explores the association between behavioral outcomes and HRT in boys ages 7-12. Patients were divided into 4 groups based on HRT status: untreated, early hormonal treatment (EHT), hormonal booster therapy (HBT), and both EHT and HBT. Analysis of Variance (ANOVA) and Kruskal-Wallis tests were conducted to determine group differences on the Child Behavior Checklist (CBCL) and the Behavior Rating Inventory of Executive Function (BRIEF). The treated groups were found to have better scores in emotional control, initiative, organization of materials, behavioral rating index, metacognition index, and global executive composite than the untreated group on the BRIEF. On the CBCL, the treated groups presented better scores for somatic complaints, social problems, thought problems, attention problems, aggressive behavior, internalizing problems, total problems, affective problems, somatic problems, ADHD problems, oppositional defiant problems, and sluggish problems in comparison to the untreated group. These results offer evidence that HRT, specifically the combination of both EHT and HBT, may be successful in mitigating some undesirable behavioral outcomes. Further research is necessary to determine the efficacy of the combination of EHT and HBT regarding dosage, specific ages, and long-term benefits.
Identifiants
pubmed: 37510306
pii: genes14071402
doi: 10.3390/genes14071402
pmc: PMC10379663
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Genet Med. 2022 Jun;24(6):1274-1282
pubmed: 35341653
Am J Med Genet C Semin Med Genet. 2015 Jun;169(2):150-7
pubmed: 25939399
Cereb Cortex. 2016 Jan;26(1):70-9
pubmed: 25146371
Ultrasound Obstet Gynecol. 2017 Sep;50(3):302-314
pubmed: 28397325
J Autism Dev Disord. 2008 Oct;38(9):1634-41
pubmed: 18324463
Pediatr Endocrinol Rev. 2010 Dec;8 Suppl 1:151-9
pubmed: 21217607
J Clin Endocrinol Metab. 2003 Feb;88(2):622-6
pubmed: 12574191
Pediatrics. 1989 Oct;84(4):678-82
pubmed: 2780130
PLoS One. 2018 Jul 23;13(7):e0200882
pubmed: 30036387
Horm Res. 2005;64(1):39-45
pubmed: 16088206
Am J Med Genet C Semin Med Genet. 2013 Feb 15;163C(1):27-34
pubmed: 23359595
Ultrasound Obstet Gynecol. 2023 Aug;62(2):266-272
pubmed: 36929222
Genes Brain Behav. 2015 Feb;14(2):200-8
pubmed: 25684214
Eur J Hum Genet. 2008 Feb;16(2):163-70
pubmed: 18000523
Am J Med Genet A. 2019 Dec;179(12):2374-2381
pubmed: 31577063
J Endocr Soc. 2019 Sep 26;3(12):2276-2285
pubmed: 31737857
J Pediatr. 2008 May;152(5):716-22
pubmed: 18410780
Am J Med Genet A. 2019 Mar;179(3):423-428
pubmed: 30637954
Am J Med Genet A. 2021 Dec;185(12):3567-3575
pubmed: 32725750
BMJ Open. 2012 Feb 22;2(1):e000650
pubmed: 22357573
Clin Genet. 1981 Aug;20(2):141-6
pubmed: 7307310
Am J Med Genet A. 2020 Aug;182(8):1881-1889
pubmed: 32220052
Genet Med. 2021 Jun;23(6):1017-1022
pubmed: 33627828